While the global scientific community is actively developing therapeutics and vaccines for COVID-19, healthcare services and translational research of other “non-urgent” illnesses have been shelved (Ledford, 2020). The sudden pause has brought inevitable changes or delays in cancer treatment (Upadhaya et al., 2020) and increased COVID-19-related mortality in cancer patients (Mehta et al., 2020). These impacts on cancer research and clinical practice could be far-reaching post-pandemic (Colbert et al., 2020) unless current modes of clinical trials are re-evaluated and contingency measures are proactively planned.
from Cancer Cell https://ift.tt/38AoSYe
from Cancer Cell https://ift.tt/38AoSYe